The authors welcome interest in their meta-analysis of individual patient data. The meta-analysis included five studies of 11,766 patients with coronary artery disease who used aspirin or clopidogrel as monotherapy to prevent ischemic events. After removing one study that caused heterogeneity, clopidogrel significantly reduced the risk of major adverse cardiovascular and cerebrovascular events (MACCE) versus aspirin (RR = 0.68, 95% CI: 0.55–0.85, P = 0.0007). Clopidogrel was associated with a lower risk of myocardial infarction and stroke compared with aspirin. Aspirin increased the risk of major bleeding according to BARC by 60% compared to clopidogrel. The results are consistent with the findings of the CAPRIE and HOST-EXAM studies.